AEMD Stock — Aethlon Medical Inc

Aethlon Medical Inc (AEMD)

Updated October 2, 2026.

AEMD is a Stock. Its deepest 1-year drawdown was 96.4%.

Aethlon Medical is a San Diego-based medical therapeutic company developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company does not currently distribute dividends. This security appeals primarily to investors seeking exposure to early-stage medical device development rather than current income.

AEMD performance

Its deepest 1-year drawdown was 96.4%.

AEMD key facts

Asset type

Stock

Asset class

Equity

Inception date

11/06/1998

Distribution frequency

None

Last close

$6.45 (as of 2026-10-02)

Market cap

$4,586,827

Average volume

40932.0

Last payment date

10/15/2019

Beta

1.399

Payout ratio

0.0%

Forward P/E

0.2074

EPS

$-14.65

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AEMD risks and drawbacks

The deepest 1-year drawdown on record here is 96.4%.

Who may consider AEMD — and who may not

It is a weaker fit for investors who need monthly cash flow (AEMD does not currently distribute); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Frequently asked questions